XRTX - XORTX Therapeutics Inc.
XORTX Therapeutics Inc.
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
403 455 7727
https://www.xortx.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3
Leitende Angestellte
| Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
|---|---|---|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, Pres & Director | 365,15k | N/A | 1960 |
| Mr. Amar Keshri C.A., CPA | Chief Financial Officer | 157,79k | N/A | 1978 |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 232,64k | N/A | 1950 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Bus. Officer | 86,11k | N/A | 1974 |
| Nick Rigopoulos | Director of Communications | N/A | N/A | N/A |
| Dr. David Sans M.B.A., Ph.D. | Director of Corp. Devel. | N/A | N/A | N/A |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | N/A | N/A | 1964 |
| Ms. Charlotte May | Corp. Sec. | N/A | N/A | N/A |
Beschreibung
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
Corporate Governance
XORTX Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.
